Program

Recent Research Advances in Drug-Induced Liver Injury 2009

A national/international discussion of recent new findings in the field of drug-induced liver injury (DILI), work in progress, and work that needs to be done.

The program is being co-sponsored by the Food and Drug Administration/Center for Drug Evaluation and Research (FDA/CDER), the Pharmaceutical Research and Manufacturers of America (PhRMA), and the American Association for the Study of Liver Disease (AASLD).

National Labor College, Silver Spring MD, 8-9 April 2009
10000 New Hampshire Avenue at Powder Mill Road, Silver Spring MD 20903

Wednesday, 8 April

7:30	*Continental Breakfast*	
8:00	Introductions and Brief Opening Statements	Janet Woodcock, FDA/CDER Alan Goldhammer, PhRMA Neil Kaplowitz, AASLD

8:15 Session I: Moderator, Roger Ulrich, CalistogaPharma

Session IA: Genetic susceptibility to DILI or liver disease

8:15	Systems biology approach to ximelagatran injury	Karin Cederbrant, AZ
8:45	MHC II haplotype marker for lumiracoxib injury	Tim Wright, Novartis
9:15	Powerful HLA marker of flucloxicillin injury susceptibility	Ann Daly, U Newcastle
9:45	*Break*	

Session IB: Can animals be used to show idiosyncratic responses?

10:15	The mouse as a model for susceptibility to DILI	Ivan Rusyn, UNC
10:45	Idiosyncrasy in ordinary laboratory animals	John Senior, FDA
11:15	Mouse models of halothane-induced liver injury	Cynthia Ju, U CO
11:45	Discussion of material presented in IA and IB	All
12:15	*Lunch*	

1:15 Session II: Moderator, Paul Watkins, UNC

Session IIA: Findings from DILI genetic networks

1:15	Findings from the SAEC international network	Matt Nelson, GSK
2:00	The Spanish DILI network	Raul Andrade, U Malaga
2:45	General discussion – panel of speakers above, audience	Panel; All
3:15	*Break*	

Session IIB: What do the gene findings mean for DILI mechanisms?

3:45	Genotype-phenotype relationships	Roger Ulrich, Calistoga
4:15	Implications of genetic susceptibility to DILI	David Goldstein, Duke U
4:45	Mechanisms of liver injury in susceptible people	Neil Kaplowitz, USC
5:15	General discussion –speakers and audience	All
6:00 – 7:00	*Reception: wine and cheese, mingle and relax --- Dinner on your own*	

Thursday, 9 April

7:30	*Continental Breakfast*	
8:00	**Session III: Moderator, Leonard Seeff, NIH**	
Session IIIA: Research in Progress A		
8:00	Screening populations for transaminase elevations	Heide Stirnadel, GSK-UK
8:20	Metabolic effects in subjects taking acetaminophen	Tom O'Connell, UNC
8:40	Update on acetaminophen hepatotoxicity	Will Lee, UTSW
9:00	Liver injury in patients on anti-tuberculosis therapy	Jussi Saukkonen, Bost U
9:20	General discussion, panelists and audience	All
10:00	*Break*	
Session IIIB: Research in Progress B		
10:30	Cellular imaging of hepatocytes to predict clinical DILI	Michael Aleo, Pfizer
10:50	Blood transcriptomic findings in acute liver injury	Rick Paules, NIEHS
11:10	Human hepatocyte cultures for study of DILI	Sangeeta Bhatia, MIT
11:30	Update on liver transplants for DI-ALF	Arie Regev, Lilly
11:50	General discussion –speakers and audience	All
12:30	*Lunch*	
	Session IV: Moderator, Lana Pauls, FDA	
	Session IV: Research that Needs to be Done	
1:30	Research opportunities under the new FDA guidance	Mark Avigan, FDA/CDER
1:55	eDISH-like methods to track hepatotoxicity: case studies	Jack Ostroff, Pfizer
2:20	IOM and DILIN suggestions and plans	Paul Watkins, The Hamner
2:40	In silico simulation of DILI using the Entelos platform	Harvey Clewell, The Hamner
3:00	*Adjourn*	

For details and changes follow information posted at website: http://ww.fda.gov/cder/livertox
Registration by AASLD: $400 for industry; $200 for government or academia
(go to http://www.aasld.org , Meetings, Hepatotoxicity Special Interest Group Meeting)
Lodging reservations on your own at NLC (http://www.nlc.edu under "For Current Students," click on Reserve a Room, group ID 3568, password 37000175; send copy to lana.pauls @fda.hhs.gov)
or at Silver Spring Hotels